The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here.
Also, lets not forget that the test provides information through the maternal line i.e., if i remember correctly the mother and any future siblings would also be allergic to aminoglycoside.
This would indeed support the health economics of all preterm babies being tested.
Its a shame we didn't have an investmeetcompany presentation coming shortly - these and similar questions could then be fielded to James Cheek.
GLA.
Stephen11.
Good info sharing Rud20 and thankyou - please post more often
I suppose it makes good sense if all preterm babies be tested on arrival, meaning that the correct antibiotics could be administered in a timely manner if needed. This model would significantly increase revenues.
Good question as to whether or not this is new. I had previously believed only the infants that needed an antibiotic were tested - I’ll do some more digging on this when time permits.
Maybe some of the other long term holders would have a view on this?
Stephen11.
Cheers john, Bighammer, and Eureka - great info sharing.
Your point 4 is most relevant for the MTRNR-1 Eureka - "best value for patients and taxpayers." The hearing loss assay prevents lifelong hearing loss and the need for Cochlear implants.
That said, forget about the shareprice for a moment - for those premature babies, that get treated with the correct medication because of this test, this is lifechanging.
I have healthy twin daughters who were born premature some years ago myself, and received exceptional care and treatment in a neonatal ward.
For these reasons i'll always be a firm GDR supporter.
GLA.
Stephen11.
So, how is the new CEO doing - lets have a look at what has been achieved and what we can look forward to!
*****The Future - Near Term*****
- James said: Revenue and commercial traction for the hearing loss test imminent - as soon as Dec 23 and Jan 24 (Brighton adopted the test and came live in December 4th 2023, and we now hear of the possibility that the 11 neonatal units in Kent, Surrey, and Sussex should go live soon. Additionally, as per 20th Dec RNS, initial overseas orders have been received from France, Austria, Greece, Saudi Arabia, Turkey and the Netherland) - i'd say that's pretty good progress from a man who has kept his word
- 100% clarity from the new CEO that special commissioning for the hearing loss test will happen - we'll watch this space, but momentum appears to be growing
- Contracts being drawn up with potential partners who can help with the FDA application for the hearing loss product in a cost effective manner - hope we hear about this soon
- NICE full validation for the MTRNR1 is being hindered by the EVO procedure and not the product - news due Jan 2024
- NICE Review of the CYP2CI9 - due Jan 2024
- More grant funding is also a possibility e.g., through MedTech etc.
*****Funding*****
- Funding: Q1 2024 - funding will be specifically for FDA of the MTRNR1 - RF drawdowns, sales, and tax credits will cover the monthly cash burn, despite what the derampers say!
- I must remind everyone that Q1 runs to the 31st March 2024, so funding for FDA doesn't necessarily need to be imminent. Additionally, other funding options are available for FDA, such as a JV or some form of American partner deal, as JC eluded to
GLA.
Stephen11.
Interesting conversation thread this morning, but to add balance, take note of what James Cheek said about the specialist commissioning of the MTRNR1 Test - the "100% clarity its happening" comment in particular.
From 23 minutes onwards in the GDR investormeetcompany presentation James Cheek is speaking about early adoption of the MTRNR1 hearing loss test through the NHS Special Commissioning programme.
He states "Pretty much got absolute 100% clarity that it is happening...big driver is to make sure it happens as quickly as possible." For the cynics amongst you, please listen to the presentation.
What is Special Commissioning? (info taken from NHS website)
- Special Commissioning is used to ensure smaller population have access to adequate medical provision to meet their specific needs. The population size can be as low as a few thousand or as many as 100,000
* Massive tick for GDR as there are 60,000 premature babies born in the UK per year
- Certain cohorts of the products and populations are prioritised for special commissioning. These include babies, infants, and children
* Massive tick for GDR
- The NHS 2022/23 budget for special commissioning was 22.9 billion and is increasing in 2023/23
* Massive tick for GDR
In a de facto manner Special Commissioning could be as good as full NICE accreditation.
GLA.
Stephen11.
Thanks John - that’s quite a large and densely populated area: Kent, Surrey, and Sussex - I’ll dig around later to see how many specialist neo-natal units the trust has and feedback to this forum.
Agreed Stims - word is spreading in the medical community and things are starting to happen 😊.
All the companies below have large American divisions - take your pick.
James Cheek has previously worked for three of the worlds leading diagnostic companies. That is:
Cepheid - Revenue for 2022 - $4.3 Billion
Beckman Coulter - Revenue for 2022 - $4.7 Billion
Roache Diagnostics Division - Revenue for 2022 - $17.7 Billion
In roles within these companies he had extensive involvement in selling directly to the NHS. Additionally, his experience from being a Director of the British In Vitro Diagnostic Association (BIVDA) should prove invaluable, given this organisations close working relationships and previous collaborations with the NHS.
GLA.
Stephen11.
Can i just echo the valid point about AIM share prices being driven by sentiment - two examples below:
- May 5th 2020: GDRs SP was £2.19 (on the rumour of the COVID test - the government opted for inferior Chinese tests, but that's another story)
- Feb 12th May 2021: GDRs SP was £1.48 (on the back of the Beckman Coulter deal and FDA application for the COVID test, although unfortunately the Americans preferred their own tests).
The difference now is we have world firsts, in the AHIL and Stroke tests operating in a much less saturated market place.
The future is bright.
Stephen11.
Https://ndau-maps.github.io/UnitMap2020/
Here is a map of all the neonatal units in the UK. Wouldn’t it be great to have an MTRNR1 test machine in each location.
It will happen through commissioning some day 😊.
GLA.
Stephen11.
Let's not forget that the MTRNR1 test can and has saved children from lifelong hearing loss as it prevents adverse drug reactions from certain medications that premature babies may require. The test allows for an alternative and more suitable medication to be administered within a speedy, yet critical time frame. It's also the only test of its kind in the world.
I'm thinking that irrespective of full NICE accreditation we may see a type of de-facto adoption when between 5 and 10 NHS Trusts acquire the test around the UK.
Let's think about this!?
If Manchester, Brighton, Edinburgh, and Belfast Trusts were saving children from lifelong hearing loss it would be extremely unfair if premature babies from neighboring Trusts (Liverpool, Kent, Glasgow, or Craigavon) didn't have access to the same test. In this sense after a certain amount of adoption and success, the test should sell itself.
GLA.
Stephen11
Interesting conversation thread this morning, but to add balance, take note of what James Cheek said about the specialist commissioning of the MTRNR1 Test - the "100% clarity its happening" comment in particular.
From 23 minutes onwards in the GDR investormeetcompany presentation James Cheek is speaking about early adoption of the MTRNR1 hearing loss test through the NHS Special Commissioning programme.
He states "Pretty much got absolute 100% clarity that it is happening...big driver is to make sure it happens as quickly as possible." For the cynics amongst you, please listen to the presentation.
What is Special Commissioning? (info taken from NHS website)
- Special Commissioning is used to ensure smaller population have access to adequate medical provision to meet their specific needs. The population size can be as low as a few thousand or as many as 100,000
* Massive tick for GDR as there are 60,000 premature babies born in the UK per year
- Certain cohorts of the products and populations are prioritised for special commissioning. These include babies, infants, and children
* Massive tick for GDR
- The NHS 2022/23 budget for special commissioning was 22.9 billion and is increasing in 2023/23
* Massive tick for GDR
In a de facto manner Special Commissioning could be as good as full NICE accreditation.
GLA.
Stephen11.